Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 2
2015 1
2016 2
2017 1
2018 6
2019 9
2020 13
2021 11
2022 12
2023 11
2024 8
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.
Maffioli M, Mora B, Ball S, Iurlo A, Elli EM, Finazzi MC, Polverelli N, Rumi E, Caramella M, Carraro MC, D'Adda M, Molteni A, Sissa C, Lunghi F, Vismara A, Ubezio M, Guidetti A, Caberlon S, Anghilieri M, Komrokji R, Cattaneo D, Della Porta MG, Giorgino T, Bertù L, Brociner M, Kuykendall A, Passamonti F. Maffioli M, et al. Among authors: elli em. Blood Adv. 2022 Mar 22;6(6):1855-1864. doi: 10.1182/bloodadvances.2021006889. Blood Adv. 2022. PMID: 35130339 Free PMC article.
Idiopathic erythrocytosis: a germline disease?
Elli EM, Mauri M, D'Aliberti D, Crespiatico I, Fontana D, Redaelli S, Pelucchi S, Spinelli S, Manghisi B, Cavalca F, Aroldi A, Ripamonti A, Ferrari S, Palamini S, Mottadelli F, Massimino L, Ramazzotti D, Cazzaniga G, Piperno A, Gambacorti-Passerini C, Piazza R. Elli EM, et al. Clin Exp Med. 2024 Jan 20;24(1):11. doi: 10.1007/s10238-023-01283-y. Clin Exp Med. 2024. PMID: 38244120 Free PMC article.
Cardiovascular events and intensity of treatment in polycythemia vera.
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group. Marchioli R, et al. N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8. N Engl J Med. 2013. PMID: 23216616 Free article. Clinical Trial.
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.
Rocca B, Tosetto A, Petrucci G, Rossi E, Betti S, Soldati D, Iurlo A, Cattaneo D, Bucelli C, Dragani A, Di Ianni M, Ranalli P, Palandri F, Vianelli N, Beggiato E, Lanzarone G, Ruggeri M, Carli G, Elli EM, Renso R, Randi ML, Bertozzi I, Loscocco GG, Ricco A, Specchia G, Vannucchi AM, Rodeghiero F, De Stefano V, Patrono C; Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators. Rocca B, et al. Among authors: elli em. Am J Hematol. 2024 Aug;99(8):1462-1474. doi: 10.1002/ajh.27418. Epub 2024 Jun 15. Am J Hematol. 2024. PMID: 38877813 Free article. Clinical Trial.
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
Crespiatico I, Zaghi M, Mastini C, D'Aliberti D, Mauri M, Mercado CM, Fontana D, Spinelli S, Crippa V, Inzoli E, Manghisi B, Civettini I, Ramazzotti D, Sangiorgio V, Gengotti M, Brambilla V, Aroldi A, Banfi F, Barone C, Orsenigo R, Riera L, Riminucci M, Corsi A, Breccia M, Morotti A, Cilloni D, Roccaro A, Sacco A, Stagno F, Serafini M, Mottadelli F, Cazzaniga G, Pagni F, Chiarle R, Azzoni E, Sessa A, Gambacorti-Passerini C, Elli EM, Mologni L, Piazza R. Crespiatico I, et al. Among authors: elli em. Blood. 2024 Apr 4;143(14):1399-1413. doi: 10.1182/blood.2023021349. Blood. 2024. PMID: 38194688 Free article.
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.
Palandri F, Elli EM, Morsia E, Benevolo G, Tiribelli M, Beggiato E, Bonifacio M, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Iurlo A, Isidori A, Bosi C, Guglielmana V, Venturi M, Dedola A, Loffredo M, Fontana G, Duminuco A, Moioli A, Tosoni L, Scalzulli E, Cattaneo D, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Vianelli N, Cavo M, Palumbo GA, Branzanti F, Breccia M. Palandri F, et al. Among authors: elli em. Cancer. 2024 Dec 15;130(24):4257-4266. doi: 10.1002/cncr.35489. Epub 2024 Jul 30. Cancer. 2024. PMID: 39078647 Free PMC article.
Breakthrough infections in MPN-COVID vaccinated patients.
Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas MA, Rumi E, Elli EM, Lunghi F, Gasior Kabat M, Cuevas B, Guglielmelli P, Bonifacio M, Marchetti M, Alvarez-Larran A, Fox L, Bellini M, Daffini R, Benevolo G, Carreno-Tarragona G, Patriarca A, Al-Ali HK, Andrade-Campos MMM, Palandri F, Harrison C, Foncillas MA, Osorio S, Koschmieder S, Magro Mazo E, Kiladjian JJ, Bolaños Calderón E, Heidel FH, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Sanchez AM, Hernandez-Boluda JC, Lopez Abadia E, Carli G, Sagues Serrano M, Kusec R, Xicoy Cirici B, Guenova M, Navas Elorza B, Angona A, Cichocka E, Kulikowska de Nałęcz A, Cattaneo D, Bucelli C, Betti S, Borsani O, Cavalca F, Carbonell S, Curto-Garcia N, Benajiba L, Rambaldi A, Vannucchi AM. Barbui T, et al. Among authors: elli em. Blood Cancer J. 2022 Nov 15;12(11):154. doi: 10.1038/s41408-022-00749-8. Blood Cancer J. 2022. PMID: 36379921 Free PMC article. No abstract available.
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study.
Palandri F, Breccia M, Morsia E, Elli EM, Benevolo G, Tiribelli M, Beggiato E, Farina M, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Isidori A, Dedola A, Scalzulli E, Moioli A, Cavalca F, Caserta S, Duminuco A, Martino B, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Bonifacio M, Palumbo GA, Branzanti F, Iurlo A, Abruzzese E. Palandri F, et al. Among authors: elli em. Leuk Res. 2025 Jul;154:107719. doi: 10.1016/j.leukres.2025.107719. Epub 2025 May 27. Leuk Res. 2025. PMID: 40460507 No abstract available.
74 results